Zacks lowered shares of Omnicell (NASDAQ:OMCL) from a neutral rating to an underperform rating in a research report released on Friday morning, Analyst RN reports. Zacks currently has $22.00 price objective on the stock.
Zacks’ analyst wrote, “Omnicell reported an uninspiring third quarter with adjusted EPS and revenues both unable to beat the Zacks Consensus Estimate. Although balanced segmental improvement was seen on the back of solid win of U.S. government orders, we are concerned with the escalating product costs and operating expenses. The company expects this to continue even in the coming quarter as unfavorable product mix will lead to drag in gross margin. Meanwhile, the company continues to face competitive pressure in the medication management and supply chain solutions market from larger players. Additionally, constrained hospital spending remains an overhang. Although Omnicell is optimistic about its three-leg strategy, the near-term visibility is still not clear. Thus, we downgrade Omnicell to Underperform. “
In other Omnicell news, Director Randy Lindholm unloaded 3,587 shares of the company’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $23.00, for a total value of $82,501.00. Following the completion of the transaction, the director now directly owns 26,917 shares of the company’s stock, valued at approximately $619,091. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
A number of other analysts have also recently weighed in on OMCL. Analysts at Cowen and Company raised their price target on shares of Omnicell from $21.00 to $24.00 in a research note to investors on Friday, November 1st. They now have a market perform rating on the stock. Separately, analysts at Craig Hallum downgraded shares of Omnicell from a buy rating to a hold rating in a research note to investors on Friday, November 1st. Finally, analysts at FBR & Co. upgraded shares of Omnicell from a market perform rating to an outperform rating in a research note to investors on Thursday, October 31st. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and three have issued a buy rating to the company. Omnicell has a consensus rating of Hold and a consensus target price of $24.20.
Omnicell (NASDAQ:OMCL) traded down 0.41% on Friday, hitting $24.1801. The stock had a trading volume of 97,438 shares. Omnicell has a 52 week low of $14.68 and a 52 week high of $25.22. The stock has a 50-day moving average of $23.52 and a 200-day moving average of $21.67. The company has a market cap of $849.5 million and a price-to-earnings ratio of 37.94.
Omnicell (NASDAQ:OMCL) last released its earnings data on Thursday, October 31st. The company reported $0.31 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.28 by $0.03. The company had revenue of $94.03 million for the quarter, compared to the consensus estimate of $94.96 million. During the same quarter in the previous year, the company posted $0.29 earnings per share. The company’s revenue for the quarter was up 11.5% on a year-over-year basis. Analysts expect that Omnicell will post $1.07 EPS for the current fiscal year.
Omnicell, Inc (NASDAQ:OMCL) is a provider of automated solutions for hospital medication and supply management.
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.